期刊
CLINICAL AND TRANSLATIONAL MEDICINE
卷 4, 期 -, 页码 -出版社
JOHN WILEY & SONS LTD
DOI: 10.1186/s40169-015-0075-0
关键词
KRAS mutant NSCLC; MAPK pathway; Targeted therapy
资金
- UPCI LUNG SPORE [P50 CA9045440]
- LUNGevity Foundation
- V Foundation
- Sidney Kimmel Foundation for Cancer Research
- Doris Duke Charitable Foundation
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS-RAF-MEK-ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据